AbbVie Inc. Selling, General and Administrative (SG&A) Expenses Growth

Selling, General and Administrative (SG&A) Expenses Growth of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Selling, General and Administrative (SG&A) Expenses Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Selling, General and Administrative (SG&A) Expenses Growth for the quarter ending March 30, 2021 was 63.11% (a 6.69% increase compared to previous quarter)
  • Year-over-year quarterly Selling, General and Administrative (SG&A) Expenses Growth increased by 48.28%
  • Annual Selling, General and Administrative (SG&A) Expenses Growth for 2020 was 47.33% (a -658.8% decrease from previous year)
  • Annual Selling, General and Administrative (SG&A) Expenses Growth for 2019 was -8.47% (a -133.19% decrease from previous year)
  • Annual Selling, General and Administrative (SG&A) Expenses Growth for 2018 was 25.52% (a 4016.13% increase from previous year)
  • Twelve month Selling, General and Administrative (SG&A) Expenses Growth ending March 30, 2021 was 57.77% (a 36.03% increase compared to previous quarter)
  • Twelve month trailing Selling, General and Administrative (SG&A) Expenses Growth increased by 798.44% year-over-year
Trailing Selling, General and Administrative (SG&A) Expenses Growth for the last four month:
30 Mar '21 30 Dec '20 29 Sep '20 29 Jun '20
57.77% 42.47% 26.24% 6.43%
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Selling, General and Administrative (SG&A) Expenses Growth of AbbVie Inc.

Most recent Selling, General and Administrative (SG&A) Expenses Growthof ABBV including historical data for past 10 years.

Interactive Chart of Selling, General and Administrative (SG&A) Expenses Growth of AbbVie Inc.

AbbVie Inc. Selling, General and Administrative (SG&A) Expenses Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 63.11%
2020 59.15% 65.9% 42.56% -0.12% 47.33%
2019 1.14% -13.65% -6.02% -6.2% -8.47%
2018 -1.38% 31.71% 16.63% 30.44% 25.52%
2017 16.5% 5.5% 2.93% 1.33% 0.62%
2016 -3.34% -6.31% -13.92% -8.01% -9.14%
2015 -48.01% -7.59% 17.61% 9.93% -17.31%
2014 130.73% 26.49% 2.99% 8.33% 44.32%
2013 2.62% 16.22% 12.84% -0.8% 7.28%
2012 -70.08% -7.89% -15.35%
2011 54.29%
2010 14.08%

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.